CMS assigned a permanent, product-specific J-code for Syfovre for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Apellis Pharmaceuticals.
The code, J2781, goes into effect Oct. 1.
The FDA approved Syfovre (pegcetacoplan injection) in February, making it the first approved treatment for geographic atrophy (GA).
“The permanent J-code is a significant milestone that will help ensure accurate and efficient reimbursement of Syfovre in all treatment settings, building on our goal of bringing this important treatment to GA